JPRN-UMIN000020527RecruitingPhase 2
Multi-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of oral inosine on the onset of wearing off in patients with early stage Parkinson's disease - Randomized clinical trial to assess the disease modifying effect of oral inosine for patients with Parkinson's disease
Ehime University Graduate School of Medicine0 sites100 target enrollmentStarted: February 1, 2016Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Enrollment
- 100
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •A history of kidney stones, gout(or chronic arthritis), ischemic heart disease A history of kidney failure of eGFR <= 60 at the screening visit. Having uncontrolled hypertension which is defined as SBP>=160 or DBP >=100 Current treatment with medication which slows urate excretion, which is defined as taking diuretics, losartan, anti-tuberculosis drugs or immune-suppression agents. Being pregnant or having an intention to become pregnant during the study period. Other factors that investigators deem inappropriate to enroll for the trial. (e.g. Having malignancy, arthritis which is difficult to discern from gout, severe allergic history to drugs)
Investigators
Similar Trials
Active, not recruiting
Phase 1
A study to find out which dose of daridorexant is safe and effective to treat insomnia in children and adolescents 10 to <18 years oldInsomnia DisorderEUCTR2021-003867-87-BEIdorsia Pharmaceuticals Ltd150
Active, not recruiting
Phase 1
A study to find out which dose of daridorexant is safe and effective to treat insomnia in children and adolescents 10 to <18 years oldInsomnia DisorderEUCTR2021-003867-87-DEIdorsia Pharmaceuticals Ltd150
Completed
Phase 2
The efficacy of Homeopathic medicines in the prevention of COVID-19 in Quarantined or Exposed IndividualsCTRI/2020/05/025491ife Force Foundation Trust2,233
Active, not recruiting
Phase 1
Double-blind, Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Characterize the Efficacy, Safety, and Tolerability of 24 Weeks of Evolocumab for Low Density Lipoprotein-Cholesterol (LDL-C) Reduction, as Add-On to Diet and Lipid-Lowering Therapy, in Pediatric Subjects 10 to 17 Yearsof Age With Heterozygous Familial Hypercholesterolemia (HeFH)Heterozygous familial hypercholesterolaemiaMedDRA version: 18.0Level: LLTClassification code 10057079Term: Heterozygous familial hypercholesterolemiaSystem Organ Class: 100000004850EUCTR2014-002277-11-ITAmgen Inc158
Active, not recruiting
Phase 1
Study to assess the long term safety and efficacy of evolocumab in children aged 10 to 17 years with Heterozygous Familial HypercholesterolemiaHeterozygous familial hypercholesterolemiaMedDRA version: 20.0Level: LLTClassification code 10057079Term: Heterozygous familial hypercholesterolemiaSystem Organ Class: 100000004850EUCTR2014-002277-11-PTAmgen Inc150